The European pharma industry has released a new report offering recommendations to improve outcomes for people living with a cardiovascular disease (CVD) in the 13 May 2022
Swiss pharma giant Novartis has announced that the European Commission (EC) has approved Jakavi (ruxolitinib) in acute or chronic graft-versus-host disease (GvH 9 May 2022
The European Commission (EC) has approved the use of Cabometyx (cabozantinib) as a monotherapy for adults with locally advanced or metastatic differentiated thy 3 May 2022
The European pharma industry has commissioned a report on drug affordability which highlights its message that overall expenditure on therapies has remained sta 7 April 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.